TABLE 3.
Plasma Apo profile of ALL survivors and controls
| Healthy Controls | ALL Survivors | |||
| Entire Group | Subgroup without Dyslipidemia | Subgroup with Dyslipidemia | ||
| Total | ||||
| Apos | ||||
| A-I (g/l) | 2.64 ± 0.09 (22) | 2.28 ± 0.06 (79)a | 2.35 ± 0.07 (40)b | 2.22 ± 0.09 (39)a |
| A-IV (μg/ml) | 1.22 ± 0.12 (22) | 1.28 ± 0.06 (53) | 1.22 ± 0.09 (27) | 1.34 ± 0.08 (26) |
| B-100 (g/l) | 0.69 ± 0.02 (22) | 0.85 ± 0.02 (78)c | 0.86 ± 0.03 (39)c | 0.83 ± .03 (39)a |
| C-II (μg/ml) | 111.6 ± 6.82 (21) | 131.9 ± 4.26 (80)b | 123.3 ± 5.27 (40) | 140.2 ± 6.51 (40)b,d |
| C-III (μg/ml) | 76.05 ± 3.47 (22) | 86.22 ± 11.62 (79) | 73.15 ± 11.60 (39)b | 98.95 ± 19.93 (40) |
| E (μg/ml) | 34.60 ± 0.91 (22) | 31.70 ± 0.91 (80) | 29.82 ± 0.98 (40)a | 33.59 ± 1.48 (40)d |
| Ratios | ||||
| C-II/C-III | 1.50 ± 0.83 (21) | 2.53 ± 0.24 (79)a | 2.81 ± 0.42 (39)a | 2.25 ± 0.22 (40)b |
| B-100/TG | 0.82 ± 0.06 (22) | 0.99 ± 0.06 (78) | 1.30 ± 0.10 (39)c | 0.69 ± 0.05 (39)b,e |
| B-100/A-I | 0.27 ± 0.01 (22) | 0.38 ± 0.01 (78)c | 0.37 ± 0.01 (39)c | 0.39 ± 0.02 (39)c |
| Children | ||||
| Apos | ||||
| A-I (g/l) | 2.41 ± 0.12 (10) | 2.19 ± 0.07 (40) | 2.26 ± 0.07 (27) | 2.03 ± 0.14 (13)b,d |
| A-IV (μg/ml) | 1.34 ± 0.24 (10) | 1.22 ± 0.09 (27) | 1.23 ± 0.12 (21) | 1.15 ± 0.10 (6) |
| B-100 (g/l) | 0.73 ± 0.03 (10) | 0.85 ± 0.03 (40)b | 0.84 ± 0.03 (27) | 0.87 ± 0.05 (13)b |
| C-II (μg/ml) | 109.3 ± 6.75 (9) | 131.2 ± 5.55 (40)b | 124.1 ± 6.84 (27) | 146.1 ± 8.37 (13)a |
| C-III (μg/ml) | 81.60 ± 3.67 (10) | 78.03 ± 11.33 (39) | 77.62 ± 16.43 (26)b | 78.85 ± 9.73 (13) |
| E (μg/ml) | 34.19 ± 1.14 (10) | 29.79 ± 1.20 (40) | 28.56 ± 1.22 (27)b | 32.35 ± 2.62 (13) |
| Ratios | ||||
| C-II/C-III | 1.36 ± 0.06 (9) | 2.55 ± 0.36 (39)a | 2.61 ± 0.49 (26)a | 2.44 ± 0.47 (13)b |
| B-100/TG | 0.91 ± 0.09 (10) | 1.12 ± 0.10 (40) | 1.34 ± 0.12 (27)a | 0.67 ± 0.07 (13)b |
| B-100/A-I | 0.31 ± 0.02 (10) | 0.40 ± 0.02 (40)b | 0.38 ± 0.02 (27)b | 0.45 ± 0.04 (13)a |
| Adults | ||||
| Apos | ||||
| A-I (g/l) | 2.84 ± 0.11 (12) | 2.39 ± 0.09 (39)b | 2.53 ± 0.13 (13) | 2.32 ± 0.12 (26)a |
| A-IV (μg/ml) | 1.13 ± 0.10 (12) | 1.34 ± 0.09 (26) | 1.21 ± 0.14 (2) | 1.27 ± 0.13 (10) |
| B-100 (g/l) | 0.65 ± 0.03 (12) | 0.85 ± 0.03 (38)a | 0.92 ± 0.04 (12)c | 0.82 ± 0.04 (26)b |
| C-II (μg/ml) | 113.3 ± 11.07 (12) | 132.6 ± 6.54 (40) | 122.5 ± 8.15 (13) | 137.4 ± 8.81 (27) |
| C-III (μg/ml) | 71.42 ± 5.12 (12) | 94.20 ± 20.21 (40) | 64.23 ± 12.01 (13) | 108.6 ± 29.17 (27) |
| E (μg/ml) | 34.94 ± 1.40 (12) | 33.62 ± 1.31 (40) | 32.44 ± 1.44 (13) | 34.18 ± 1.81 (27) |
| Ratios | ||||
| C-II/C-III | 1.61 ± 0.13 (12) | 2.50 ± 0.31 (40) | 3.22 ± 0.80 (13) | 2.16 ± 0.23 (27) |
| B-100/TG | 0.75 ± 0.07 (12) | 0.88 ± 0.08 (38) | 1.23 ± 0.14 (12)a | 0.71 ± 0.07 (26)f |
| B-100/A-I | 0.23 ± 0.02 (12) | 0.37 ± 0.02 (38)c | 0.38 ± 0.03 (12)c | 0.37 ± 0.03 (26)a |
Data are expressed as mean ± SEM (n).
a
P < 0.01 versus healthy controls.
b
P < 0.05 versus healthy controls.
c
P < 0.001 versus healthy controls.
d
P < 0.05 versus ALL survivors without dyslipidemia.
e
P < 0.001 versus ALL survivors without dyslipidemia.
f
P < 0.01 versus ALL survivors without dyslipidemia.